Compare Liberty Global Ltd Class C (LBTYK) vs Pfizer Inc (PFE) Price & Performance

Liberty Global (LBTYK) trades at $8.52, down 4.48% amid bearish technical signals. The stock shows mixed fundamentals with strong gross margins of 67.17% but significant net losses. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 missing. The company is progressing with strategic initiatives including the Ziggo Group spin-off planned for 2027 and an AI partnership with Sierra.

Despite current losses, analyst consensus remains bullish with a $12.67 price target, suggesting 49% upside. Key risks include execution of the Ziggo listing and sustained profitability challenges. The cash position and asset monetization provide downside support, while the planned 2027 value-unlock event represents the primary growth catalyst.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.